atopic dermatitis

VYNE Therapeutics Inc (NASDAQ: VYNE) reports Q2 product revenue of $4.0 million compared to $1.5 million in Q2 FY20, driven by the Zilxi product launch in October 2020 and increased demand for Amzeeq.  The gross margin decreased from 85% to 80%. The adjusted EPS loss of $(0.35...

The FDA will not meet PDUFA goal dates for Pfizer Inc's (NYSE: PFE) marketing application for abrocitinib for severe atopic dermatitis and the supplemental application for Xeljanz/Xeljanz XR (tofacitinib) for active ankylosing spondylitis.  The FDA cited its ongoing...

AbbVie Inc (NYSE: ABBV) and Eli Lilly And Co (NYSE: LLY) will have to keep waiting for a chance for their JAK inhibitors in atopic dermatitis to see the market. The companies separately said on Friday that the FDA again delayed decisions over their applications for Rinvoq (...

RAPT Therapeutics Inc (NASDAQ: RAPT) has announced topline results from its Phase 1b trial of RPT193 as monotherapy for moderate-to-severe atopic dermatitis (AD). After four weeks of treatment, patients with moderate-to-severe AD who received RPT193 showed a 36.3% improvement from...

Aclaris Therapeutics Inc (NASDAQ: ACRS) has announced preliminary topline results from its Phase 2a trial evaluating ATI-1777 for moderate to severe atopic dermatitis (AD). The primary efficacy endpoint of this trial was the percent change from baseline in the modified Eczema Area...

Amgen Inc (NASDAQ: AMGN) and Kyowa Kirin Co Ltd (OTC: KYKOF) have agreed to jointly develop and commercialize KHK4083, Kyowa Kirin's Phase 3-ready anti-OX40 fully human monoclonal antibody in development for atopic dermatitis, with potential in other autoimmune diseases. In...

Cara Therapeutics Inc (NASDAQ: CARA) shares dive after as investors react to topline results from its KARE Phase 2 trial evaluating oral Korsuva (difelikefalin tablets) for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis (AD) patients. The trial...

Incyte Corporation (NASDAQ: INCY) has announced findings from three pooled analyses of its Phase 3 studies, TRuE-AD1 and TRuE-AD2 evaluating ruxolitinib cream to treat atopic dermatitis (AD). Data presented at the American Academy of Dermatology Virtual Meeting Experience 2021...

Kindred Biosciences Inc (NASDAQ: KIN) has announced positive results from the pharmacokinetic study (KIND-039) evaluating a new long-acting interleukin (IL)-31 antibody. Results from the study demonstrated that the fully caninized, high-affinity antibody has up to a three-fold...

The FDA has extended the review period for AbbVie Inc's (NYSE: ABBV) supplemental marketing application seeking upadacitinib approval to treat adults and adolescents with moderate to severe atopic dermatitis. The action date has been extended three months to early Q3...

Analysts at Baird Equity Research turned bearish on Regeneron Pharmaceuticals Inc (NASDAQ: REGN) as investor expectation for a recently launched drug may be too high. The firm's Brian Skorney downgrades Regeneron's stock rating from Neutral to Underperform with an unchanged $408 price target....

In a public conference call on Monday, Anacor Pharmaceuticals Inc (NASDAQ: ANAC) executives announced the results of two Phase 3 trials for a topical drug to treat atopic dermatitis, more commonly known as eczema. The treatment came in the form of a topical ointment, crisaborole. Atopic dermatitis...